Suppr超能文献

由于蛋白酶80s环中协同的结构变化,一类强效HIV-1蛋白酶抑制剂的P1-P3基团的另一个结合位点。

An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease.

作者信息

Munshi S, Chen Z, Yan Y, Li Y, Olsen D B, Schock H B, Galvin B B, Dorsey B, Kuo L C

机构信息

Department of Antiviral Research, Merck Research Laboratories, West Point, PA 19486, USA.

出版信息

Acta Crystallogr D Biol Crystallogr. 2000 Apr;56(Pt 4):381-8. doi: 10.1107/s0907444900000469.

Abstract

Structures of the complexes of HIV protease inhibitor L--756,423 with the HIV-1 wild-type protease and of the inhibitors Indinavir, L-739,622 and Saquinavir with the mutant protease (9X) containing nine point mutations (Leu10Val, Lys20Met, Leu24Ile, Ser37Asp, Met46Ile, Ile54Val, Leu63Pro, Ala71Val, Val82Thr) have been determined. Comparative analysis of these structures reveals an alternate binding pocket for the P1-P3 group of Indinavir and L--756, 423. The alternate binding pocket is a result of concerted structural change in the 80s loop (residues 79-82) of the protease. The 80s loop is pulled away from the active site in order to accommodate the P1-P3 group, which is sandwiched between the flap and the 80s loop. This structural change is observed for the complexes of the wild type as well as the 9X mutant protease. The study reveals that the 80s loop is an intrinsically flexible loop in the wild-type HIV-1 protease and that mutations in this loop are not necessary to result in conformational changes. Conformation of this loop in the complex depends primarily upon the nature of the bound inhibitor and may be influenced by mutations in the protease. The results underscore the need to understand the intrinsic structural plasticity of the protease for the design of effective inhibitors against the wild-type and drug-resistant enzyme forms. In addition, the alternate binding pocket for the P1-P3 group of Indinavir and L--756,423 may be exploited for the design of potent inhibitors.

摘要

已确定HIV蛋白酶抑制剂L-756,423与HIV-1野生型蛋白酶形成的复合物结构,以及茚地那韦、L-739,622和沙奎那韦与含有九个点突变(Leu10Val、Lys20Met、Leu24Ile、Ser37Asp、Met46Ile、Ile54Val、Leu63Pro、Ala71Val、Val82Thr)的突变蛋白酶(9X)形成的复合物结构。对这些结构的比较分析揭示了茚地那韦和L-756,423的P1-P3基团的另一个结合口袋。该另一个结合口袋是蛋白酶80s环(残基79-82)协同结构变化的结果。80s环从活性位点拉开,以容纳夹在瓣和80s环之间的P1-P3基团。在野生型以及9X突变蛋白酶的复合物中均观察到这种结构变化。研究表明,80s环在野生型HIV-1蛋白酶中是一个固有柔性环,该环中的突变并非导致构象变化的必要条件。复合物中该环的构象主要取决于结合抑制剂的性质,并且可能受蛋白酶中突变的影响。结果强调了了解蛋白酶的固有结构可塑性对于设计针对野生型和耐药酶形式的有效抑制剂的必要性。此外,茚地那韦和L-756,423的P1-P3基团的另一个结合口袋可用于设计强效抑制剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验